PolyNovo Croissance future

Future contrôle des critères 5/6

PolyNovo devrait augmenter ses bénéfices et son chiffre d'affaires de 38.4% et de 17.5% par an respectivement. Le BPA devrait croître de de 37.8% par an. Le rendement des capitaux propres devrait être 28.1% dans 3 ans.

Informations clés

38.4%

Taux de croissance des bénéfices

37.8%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices	16.2%
Taux de croissance des recettes	17.5%
Rendement futur des capitaux propres	28.1%
Couverture par les analystes	Good
Dernière mise à jour	25 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate

Jan 08

Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?

Sep 22

When Should You Buy PolyNovo Limited (ASX:PNV)?

Jun 26

Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?

May 30

Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price

Apr 18

Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?

Mar 23

Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?

Feb 05

Returns At PolyNovo (ASX:PNV) Are On The Way Up

Nov 16

PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price

Nov 01

What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?

Jul 29

PolyNovo (ASX:PNV) Is Looking To Continue Growing Its Returns On Capital

Jun 15

Estimating The Fair Value Of PolyNovo Limited (ASX:PNV)

May 16

We Think PolyNovo (ASX:PNV) Is Taking Some Risk With Its Debt

Apr 28

There's Been No Shortage Of Growth Recently For PolyNovo's (ASX:PNV) Returns On Capital

Mar 07

Is PolyNovo (ASX:PNV) Weighed On By Its Debt Load?

Dec 13

PolyNovo Limited's (ASX:PNV) CEO Compensation Looks Acceptable To Us And Here's Why

Oct 19

Is PolyNovo (ASX:PNV) Using Debt In A Risky Way?

May 08

News Flash: 7 Analysts Think PolyNovo Limited (ASX:PNV) Earnings Are Under Threat

Feb 27

Earnings Update: PolyNovo Limited (ASX:PNV) Just Reported And Analysts Are Trimming Their Forecasts

Feb 25

Is PolyNovo Limited (ASX:PNV) Potentially Undervalued?

Feb 17

Prévisions de croissance des bénéfices et des revenus

ASX:PNV - Estimations futures des analystes et données financières antérieures (AUD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
6/30/2027	207	37	30	35	8
6/30/2026	168	23	13	21	9
6/30/2025	134	9	-9	6	9
6/30/2024	103	5	1	4	N/A
3/31/2024	93	3	-3	0	N/A
12/31/2023	83	2	-6	-3	N/A
9/30/2023	75	-2	-7	-5	N/A
6/30/2023	66	-5	-8	-7	N/A
3/31/2023	59	-6	-5	-4	N/A
12/31/2022	53	-7	-2	-2	N/A
9/30/2022	48	-4	-2	-2	N/A
6/30/2022	42	-1	-3	-2	N/A
3/31/2022	38	0	-3	-2	N/A
12/31/2021	35	1	-4	-2	N/A
9/30/2021	32	-2	-4	-1	N/A
6/30/2021	29	-5	-4	0	N/A
3/31/2021	27	-5	-6	0	N/A
12/31/2020	25	-5	-7	0	N/A
9/30/2020	24	-5	-8	0	N/A
6/30/2020	22	-4	-9	0	N/A
3/31/2020	20	-4	-11	-2	N/A
12/31/2019	18	-4	-13	-3	N/A
9/30/2019	16	-3	-11	-3	N/A
6/30/2019	14	-3	-10	-3	N/A
3/31/2019	12	-4	-8	-5	N/A
12/31/2018	9	-5	-7	-6	N/A
9/30/2018	8	-5	-7	-7	N/A
6/30/2018	7	-6	-7	-7	N/A
3/31/2018	6	-6	N/A	-7	N/A
12/31/2017	5	-6	N/A	-7	N/A
9/30/2017	4	-6	N/A	-6	N/A
6/30/2017	4	-5	N/A	-5	N/A
3/31/2017	4	-4	N/A	-4	N/A
12/31/2016	5	-3	N/A	-3	N/A
9/30/2016	4	-3	N/A	-3	N/A
6/30/2016	3	-3	N/A	-4	N/A
3/31/2016	2	-3	N/A	-4	N/A
12/31/2015	0	-2	N/A	-4	N/A
9/30/2015	0	-2	N/A	-3	N/A
6/30/2015	0	-1	N/A	-3	N/A
3/31/2015	0	-2	N/A	-2	N/A
12/31/2014	0	-3	N/A	-2	N/A
9/30/2014	0	-3	N/A	-2	N/A
6/30/2014	0	-3	N/A	-3	N/A
3/31/2014	0	-2	N/A	-3	N/A
12/31/2013	0	-2	N/A	-3	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de PNV ( 38.4% par an) est supérieure au taux d'épargne ( 2.6% ).

Bénéfices vs marché: Les bénéfices de PNV ( 38.4% par an) devraient croître plus rapidement que le marché Australian ( 12.6% par an).

Croissance élevée des bénéfices: Les bénéfices de PNV devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de PNV ( 17.5% par an) devrait croître plus rapidement que le marché Australian ( 5.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de PNV ( 17.5% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de PNV devrait être élevé dans 3 ans ( 28.1 %)

PolyNovo Croissance future

Future contrôle des critères 5/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased by 7.0% to AU$2.53

Price target increased by 8.8% to AU$2.37

Consensus EPS estimates increase by 15%

Price target increased by 9.7% to AU$2.14

Price target increased by 7.4% to AU$1.95

Price target decreased by 9.5% to AU$1.88

Recent updates

Is It Time To Consider Buying PolyNovo Limited (ASX:PNV)?

Now 21% undervalued

Independent Non-Executive Director recently sold AU$261k worth of stock

PolyNovo Limited Announces Retirement of Bruce Rathie as Non-Executive Director

Non-Executive Independent Director recently sold AU$1.9m worth of stock

Now 21% undervalued

PolyNovo Limited, Annual General Meeting, Oct 28, 2024

PolyNovo (ASX:PNV) Is Experiencing Growth In Returns On Capital

Now 20% undervalued

Price target increased by 7.0% to AU$2.53

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

Now 24% undervalued

Price target increased by 8.8% to AU$2.37

Consensus EPS estimates increase by 15%

PolyNovo Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Insufficient new directors

PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

Now 21% undervalued

Now 23% undervalued

Now 20% undervalued

Price target increased by 9.7% to AU$2.14

When Should You Buy PolyNovo Limited (ASX:PNV)?

First half 2024 earnings released: EPS: AU$0.004 (vs AU$0.006 loss in 1H 2023)

Why Investors Shouldn't Be Surprised By PolyNovo Limited's (ASX:PNV) P/S

Price target increased by 7.4% to AU$1.95

PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate

PolyNovo Limited, Annual General Meeting, Nov 03, 2023

Price target decreased by 9.5% to AU$1.88

Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?

Price target decreased by 7.8% to AU$2.07

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 65%, revenue upgraded

Forecast breakeven date pushed back to 2025

When Should You Buy PolyNovo Limited (ASX:PNV)?

Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?

Price target decreased by 11% to AU$2.25

Forecast breakeven date pushed back to 2025

Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price

Independent Non-Executive Chairman recently sold AU$9.7m worth of stock

Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?

Now 23% undervalued after recent price drop

Forecast breakeven date moved forward to 2023

First half 2023 earnings released: AU$0.006 loss per share (vs AU$0.002 profit in 1H 2022)

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

Price target increased by 13% to AU$2.36

Consensus EPS estimates upgraded to AU$0.0002 loss

Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?

Forecast breakeven date pushed back to 2024

Price target increased to AU$1.98

Price target increased to AU$1.90

Returns At PolyNovo (ASX:PNV) Are On The Way Up

PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price

Independent Non-Executive Chairman recently bought AU$202k worth of stock

PolyNovo Limited, Annual General Meeting, Oct 28, 2022

PolyNovo Limited Announces Re-Designation of David McQuillan as Chief Technical and Scientific Officer

Price target increased to AU$1.68

Full year 2022 earnings: EPS misses analyst expectations

Now 21% undervalued

PolyNovo Limited Announces First Patient Enrolled in Clinical Trial of NovoSorb SynPath Treatment for Diabetic Foot Ulcers

PolyNovo Limited Announces CEO Changes

PolyNovo Limited Announces CEO Changes

What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?

Consensus forecasts updated

Now 21% undervalued

PolyNovo (ASX:PNV) Is Looking To Continue Growing Its Returns On Capital

Independent Non-Executive Chairman recently bought AU$956k worth of stock

Now 23% undervalued